B-ALL/NHL 2002 protocol achieved a 3-year overall survival and progression-free survival of 73% in adult patients with Burkitt lymphoma/leukemia (BL). While demonstrating efficacy comparable with ...

Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone ...

Yawnick eventually got a chest X-ray under the discretion of a chiropractor ... learning he had primary mediastinal B-cell ...

Lymphoma, a complex malignancy originating in lymphocytes and lymphoid tissues, poses significant challenges for both diagnosis and treatment due to its diverse pathological subtypes. Traditional ...